Newsroom

September 2020

• Press release Sep 11, 2020

  Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)

  Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1 Subgroup analyses of the EXPAND trial showed the…
• Press release Sep 11, 2020

  Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis

  New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates and MRI lesion activity and demonstrated…
• 
  Story Sep 11, 2020 Discovery

  Not your grandparents’ nuclear medicine

  Novartis is taming nuclear power and putting it to use to treat advanced cancer.

• Featured News Sep 09, 2020

  New report shows how AI in health is critical for COVID-19 response and recovery

• Press release Sep 08, 2020

  Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum

  Novartis will present 48 abstracts from its leading MS portfolio, including new data on recently FDA-approved Kesimpta® (ofatumumab)—the first and only self-administered, targeted B-cell therapy for…
• 
  Story Sep 07, 2020 Patient Perspectives

  Reimagining asthma care: how data and digital could bring asthma management goals within reach

  Bertrand Bodson explains the Novartis strategy for digital innovation in asthma care.

• Press release Sep 07, 2020

  Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings

  High-dose, once-daily Enerzair® Breezhaler® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks1 Once-daily Enerzair…
• Press release Sep 02, 2020

  Novartis announces NEJM publication of pivotal study of Tabrecta™ in patients with METex14 metastatic non-small cell lung cancer

  Tabrecta™ (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon…
• Statement Sep 02, 2020

  AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy

• Featured News Sep 01, 2020

  Bold Advocates for Blood Cancers and Blood Disorders

  Blood diseases place a huge burden on individual patients, their families and on wider society. Yet advances in hematology treatment give so much cause for hope. It’s our responsibility to turn that hope into reality. Hear from five bold advocates who inspire us.

• Press release Sep 01, 2020

  New collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines

  The collaboration aims to help alleviate supply and logistical constraints in the African Union member states Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division…
• Ad hoc release Sep 01, 2020

  Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality

  2025 target to increase patients reached in LMICs with strategic innovative medicines by 200% and the Novartis Flagship Programs by 50% - bringing potential reach to over 23 million patients across…